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Abstract
Summary Titrated supplementations with vitamin D-fortified
yogurt, based on spontaneous calcium and vitamin D intakes,
can be cost-effective in postmenopausal women with or with-
out increased risk of osteoporotic fractures.
Introduction The objective of this study is to assess the cost-
effectiveness of the vitamin D-fortified yogurt given to wom-
en with and without an increased risk of osteoporotic fracture.
Methods Avalidated cost-effectiveness microsimulationMar-
kov model of osteoporosis management was used. Three per-
sonalized supplementation scenarios to reflect the Ca/Vit D
needs taking into account the well-known variations in dietary
habits and a possible pharmacological supplementation in Ca/
Vit D, given above or in combination with anti-osteoporosis
medications: one yogurt per day, i.e., 400mg of Ca+200 IU of
Vit D (scenario 1 U), two yogurts per day, i.e., 800 mg of Ca+
400 IU of Vit D (scenario 2 U), or three yogurts per day, i.e., 1,
200 mg of Ca+600 IU of Vit D (scenario 3 U).
Results One yogurt is cost-effective in the general population
above the age of 70 years and in all age groups in women with
low bone mineral density (BMD) or prevalent vertebral frac-
ture (PVF). The daily intake of two yogurts is cost-effective
above 80 years in the general population and above 70 years in
the two groups of women at increased risk of fractures. How-
ever, an intake of three yogurts per day is only cost-effective
above 80 years old in the general population, as well as in
women with low BMD or PVF.
Conclusions Our study is the first economic analysis
supporting the cost-effectiveness of dairy products, fortified
with vitamin D, in the armamentarium against osteoporotic
fractures.
Keywords Cost-effectiveness . Dairy products . Fracture .
Osteoporosis . Yogurt
Introduction
Osteoporosis is defined as a systemic skeletal disease charac-
terized by low bone mass and microarchitectural deterioration
of bone tissue, with a consequent increase in bone fragility and
susceptibility to fractures [1]. The high societal and personal
costs of osteoporosis pose challenges to public health and
physicians [2]. Adequate dietary intakes of key bone nutrients
such as calcium, vitamin D, and proteins contribute to bone
health and reduce the risk of fracture later in life [2–4]. A
recent European consensus recommends adequate vitamin D
intake of 800 IU/day to mainta in serum 25-OH
hydroxyvitamin D levels >50 nmol/L as well as calcium in-
take of 1000 mg/day [3, 5]. There is a high prevalence of
vitamin D insufficiencies in the elderly and dietary calcium
is low in many postmenopausal osteoporotic women [2, 5–8].
Dietary sources of nutrients are the preferred option and phar-
macological supplementation should only be targeted to those
individuals who do not get sufficient calcium from their diet
and who are at increased risk for osteoporosis [2]. As calcium
is mainly provided in dairies, calcium and vitamin D-fortified
dairy products (e.g., yogurt, milk,…) providing at least 40 %
of the recommended nutrient intake (RNI) of calcium
(400 mg) and 200 IU of vitamin D per portion are considered
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valuable options that are likely to improve long-term adher-
ence [2]. Indeed, dairy food has been shown to provide calci-
um with good compliance compared to pharmacological sup-
plements [9]. This phenomenon might be emphasized by re-
cent publications suggesting that pharmacological calcium
supplements might be associated with adverse health events
of which dairy products intake appears to be deprived [10].
Amazingly, though this recommendation is claimed to be jus-
tified both in terms in efficacy and cost-effectiveness, few
studies targeted the cost-effectiveness of calcium and vitamin
D, and none, so far, assessed the economic value of fortified
dairy products given to women at increased risk of fractures
[11, 12]. Whereas low intake in calcium and vitamin D seems
ubiquitous in most European countries [2, 6–8], there are sig-
nificant variations in the amount of these nutrients that post-
menopausal women receive, hence making the case for a per-
sonalized supplementation, tailored on their real needs rather
than systematically offering to all subjects the Bstandard^ dose
of 1 g of calcium and 800 IU of vitamin D per day. Therefore,
the objectives of this study was therefore to assess the cost-
effectiveness of the administration of one to three portions per
day of a vitamin D-fortified yogurt given to elderly women
with and without an increased risk of osteoporotic fracture.
Material and methods
Due to the previously described wide variation in calcium and
vitamin D intake in women with and without an increased risk
of osteoporosis [2, 6, 8], we considered three scenarios, i.e.,
daily administration of one, two, or three portions of a yogurt
fortified with vitamin D (each portion providing 400 mg of
calcium and 200 IU of vitamin D) to reach the recommended
daily intake of 1000 mg of calcium and 800 IU of vitamin D.
The target population focused on women aged 65, 70, or
80 years, without increased risk of osteoporosis, or with low
bonemineral density (BMD), defined as a T-score<−2.5 at the
spine and/or at the femoral neck or with a prevalent vertebral
fracture (PVF).
We adapted an extensively published and validated cost-
effectiveness model of osteoporosis management [11, 13].
The model is a microsimulation Markov model designed with
TreeAge pro (TreeAge Pro Inc, Williamston, USA). The oc-
currence of fractures at individual ages is modeled through a
health-state transition process (Markov model). Individuals
begin one at a time in the non-fracture state and progress every
6 months (cycle length) according to age-specific fracture risk
through the non-fracture state, hip fracture state, vertebral
fracture state, wrist fracture state, or other fracture state. Sim-
ilarly, individuals with a PVF begin one at a time in this state
and progress also every 6 months to other fracture states ac-
cording to age-specific fracture risk adjusted by the presence
of this prior vertebral fracture. Microsimulation modeling is a
way to integrate memory by taking into account the full his-
tory of the patient. For instance, the occurrence of fractures as
time goes by is taken into account by tracker variables to
adjust the future risks of fractures [13]. The model has a life-
time horizon for each simulated patient. All patients can die
from background mortality from any health state (Fig. 1).
The risk of hip fracture was derived from the Belgian na-
tional database of hospital bills [14]. Since the incidence of
non-hip fracture was not known, we applied the age-specific
ratio of index fracture to hip fracture in Belgium as found in
Sweden [15]. These risks of fractures in the general Belgian
population were further adjusted for women with BMD T-
score<−2.5 and women with a PVF using a method described
elsewhere [16].
We assumed that individuals who had a previous fracture
were at increased risk of a subsequent fracture at the same
location. These increased relative risks of fracture were 2.3,
4.4, 3.3, and 1.9 for hip, vertebral, wrist, and others fractures,
respectively [13, 17, 18]. An increased risk of subsequent
fractures at different sites from that of prior fractures was not
modeled in the absence of supporting data except for a subse-
quent hip fracture following a vertebral fracture with an in-
creased risk of 2.3 [13].
The age-specific mortality rates were taken from official
Belgian demographic statistics for the year 2012 (Pubic Fed-
eral Department of Economics, Brussels, 2015). We assumed
that hip fracture increased death probabilities by 1.53 in the
first 6 months following the fracture, by 1.75 in the 6–
12 months following the fracture, and by 1.78 in subsequent
year, as evidenced in a meta-analysis [19]. The same excess
mortality was assumed for vertebral fracture but not for wrist
and others fractures.
Utility data of the general population and relative fracture
disutility were taken from a published systematic review [20].
When a second fracture occurred at the same site, the disutility
applied to the first fracture was reduced by 50 % [13, 21].
Cat/Vit D supplementation effectiveness in the reduction of
fracture incidence was taken from a recent study [11] that
reviewed and synthesized meta-analyses previously published
on the subject. Ca/Vit D supplementation has been shown to
reduce the risk of hip fracture by 18 % (RR=0.82, 95 % CI
7.1–0.94; meta-analysis of 6 trials including 45,509 patients)
[22]. The risk of vertebral fracture by 13 % (RR=0.87, 95 %
Cl 0.75–1.01; meta-analysis including 45,164 patients) [23]
and the risk of non-hip non-vertebral fracture by 20 % (RR=
0.80, 95 % Cl 0.72–0.89; meta-analysis of 9 trials including
32,285 patients) [24].
Patients were assumed to follow Ca/Vit D supplementation
for 3 years. The protective effect of Ca/Vit D supplementation
on fracture risk was then assumed to decline linearly for a
period equal to the supplementation duration (i.e., 3 years).
This assumption is aligned with previous cost-effectiveness
analyses of osteoporosis treatment [1, 11, 25].
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The perspective for the cost calculation was that of the
Belgian Health care payers (government and patients) as rec-
ommended in the Belgian pharmacoeconomics guideline [26].
Only direct medical costs were taken into account. The hos-
pitalization cost of hip fracture was retrieved from the Belgian
national database of hospital bills for the year 2007. Extra
costs in the year following a hip fracture were derived from
a prospective study of 159 women [27]. The costs of non-hip
fractures were estimated relative to hip fracture [28]. We as-
sumed that non-hip fractures were not associated with long-
term costs.
In the absence of official pricing data, as opposed to phar-
maceuticals for instance, the price of dietary Ca/Vit D supple-
mentation products was derived from the observed market
prices of a yogurt containing 400 mg of Ca and 200 IU of
Vit D per unit. The average price per pack of 4 U was 1.37 €,
i.e., 0.34 € per unit.
We included the cost of one general practitioner visit (23 €)
per year of supplementation and the cost of one bone densi-
tometry at years 1 and 3 (59 €=36 € the cost of bone densi-
tometry+23 € the cost of one additional general practitioner
visit).
All costs were expressed in 2014 euros using the official
Belgian health price index (Public Federal Department of Eco-
nomics, Brussels, 2015).
Three supplementation scenarios were considered to reflect
the Ca/Vit D needs of the female population with osteoporosis
or with PVF, taking into account the well-known variations in
dietary habits and a possible pharmacological supplementa-
tion in Ca/Vit D, given above or in combination with anti-
osteoporosis medications: one enriched yogurt per day, i.e.,
400 mg of Ca+200 IU of Vit D (scenario 1 U), two enriched
yogurt units per day, i.e., 800 mg of Ca+400 IU of Vit D
(scenario 2 U), or three enriched yogurt units per day, i.e., 1,
200 mg of ca+600 IU of Vit D (scenario 3 U). With a unit
price of 0.34 € per yogurt, the annual costs were 125, 250, and
375 € for the 1 U, 2 U, and 3 U dietary Ca/Vit D supplemen-
tation scenarios, respectively.
Average costs and quality-adjusted life-years (QALYs)
were then computed and compared through an incremental
cost-effectiveness ratio (ICER). The incremental cost-
effectiveness ratio (ICER) is calculated as follows:
ICER ¼ Cost of new stratedy‐cost of current practice
Effect of new strategy‐effect of current practice
We programmed and ran 27 microsimulations: 3 age
groups (65 years, 70 years, and 80 years), 3 baseline risks
(women without low BMD or a PVF, women with a BMD
T-score<−2.5, and women with a PVF), and 3 supplementa-
tion scenarios (1 U, 2 U, or 3 U of Ca/Vit D diary supplemen-
tations per day). Each microsimulation was run 10 times with
200,000 patients to enable variability analyses. The average
ICERs with its 95 % confidence intervals were evaluated for
each of the 27 microsimulations QALYs and costs were
discounted at 1.5 and 3 % respectively.
Results
The incremental cost-effectiveness ratios of the daily intake of
1, 2, or 3 portions of a vitamin D-fortified yogurt to women
aged 65, 70, or 80 years, with no increased risk of osteoporosis
(general population), low BMD, and PVF are summarized in
Tables 1, 2, and 3 and in Fig. 2. Taking an upper limit of 45,
000 €/QALYas a threshold for cost-efficiency [26], one daily
portion of yogurt is cost-effective in the general population
above the age of 70 years and in all age groups in women
with low BMD or PVF. The daily intake of two portions of
yogurt is cost-effective above 80 years in the general popula-
tion and above 70 years in the two groups of women at in-
creased risk of fractures. However, an intake of three yogurts
per day is only cost-effective above 80 years old in all three
groups of women.
Discussion
This study is the first attempt to assess the cost-effectiveness
of the daily intake of various amounts of a dairy product sup-
plemented with vitamin D in women, at ages from 65 to
80 years and with or without prevalent osteoporosis. We se-
lected a currently marketed yogurt which, as recommended by
a recent published consensus guidance document for the man-
agement of osteoporosis [2] provides, in each portion, 40% of
the RNI of calcium (400 mg) and 200 IU of vitamin D. Our
results suggest that such a dietary supplementation in bone-
friendly nutrients is cost-effective at ages varying from 65 to
80 years, depending on the prevalence of osteoporosis and on
the number of portions required to reach the RNI. Low calci-
um intake in elderly subjects was repeatedly described, in the
Fig. 1 Model structure. Transition to death and from post-fracture (Fx)
states to any fracture states. Death and no-fracture states were excluded
from the diagram for simplicity. CV clinical vertebral fractures (from 9)
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general population [2, 29] and in osteoporotic subjects [2, 8].
A recent survey of calcium intake from calcium-dense dairy
products in fracture patients reported a wide distribution of
daily calcium intake in these patients with more than 60 %
of the subjects remaining below the RNI of 1 g/day [30]. This
is in accordance with one of our previous studies, conducted
in patients with established osteoporosis, issued from nine
European countries and showing that, while close to 40 % of
the population took pharmacological calcium supplements,
only a small subset of the patients had sufficient calcium in-
take [8]. In most studies assessing questionnaires evaluating
calcium intakes, the standard deviation amounts up to 50% of
the mean recorded value confirming large discrepancies be-
tween subjects and the need for a tailored supplementation
based on the pre-existing calcium intake [31]. Similarly, vita-
min D inadequacy is well documented in normal and osteo-
porotic subjects [5–7, 32] and the distribution of serum 25-
hydroxyvitamin D concentrations, the principal index of vita-
min D status [3, 5, 6], shows a wide scatter in the degree of
deficiency and in the subsequent need for supplementation.
Our study is the first to consider a personalized approach for
calcium and vitamin D supplementation, tailoring the
Table 1 Costs, QALYs, and ICER for a supplementation with one portion per day (125 Euros/year)
1 Unit/day (€125/year)
Ca/Vit D supplementation No supplementation Incremental ICER 95 % CI
Cost QALYs Cost QALYs Cost QALYs Low High
Women without low BMD or prevalent vertebral fracture
65 years € 6882 12.793 € 6461 12.788 € 421 0.004 € 94,304 € 18,369 € 170,239
70 years € 7556 10.183 € 7222 10.173 € 333 0.010 € 34,513 € 16,406 € 52,620
80 years € 7646 5.622 € 7701 5.605 −€ 55 0.017 −€ 3290 −€ 5036 −€ 1544
Women with low BMD
65 years € 10,447 12.655 € 10,137 12.643 € 310 0.012 € 26,596 € 8465 € 44,726
70 years € 10,823 10.074 € 10,607 10.060 € 217 0.014 € 15,183 € 10,448 € 19,918
80 years € 9464 5.571 € 9685 5.553 −€ 221 0.018 −€ 12,237 −€ 15,405 −€ 9069
Women with prevalent vertebral fracture
65 years € 9554 12.528 € 9195 12.513 € 359 0.015 € 24,345 € 14,736 € 33,954
70 years € 10,452 9.934 € 10,174 9.914 € 279 0.019 € 14,328 € 11,841 € 16,814
80 years € 10,360 5.453 € 10,614 5.426 −€ 255 0.027 −€ 9364 −€ 11,793 −€ 6934
Table 2 Costs, QALYs, and ICER for a supplementation with two portions per day (250 Euros/year)
2 Units/day (€250/year)
Ca/Vit D supplementation No supplementation Incremental ICER (€) 95 % CI
Cost (€) QALYs Cost (€) QALYs Cost (€) QALYs Low (€) High (€)
Women without low BMD or prevalent vertebral fracture
65 years 7228 12.796 6430 12.789 798 0.006 123,122 58,426 187,819
70 years 7909 10.181 7201 10.170 709 0.011 62,975 38,000 87,951
80 years 8005 5.620 7698 5.601 307 0.020 15,576 13,586 17,566
Women with low BMD
65 years 10,763 12.653 10,105 12.641 658 0.012 56,498 43,655 69,340
70 years 11,163 10.075 10,632 10.059 531 0.016 32,467 22,292 42,642
80 years 9826 5.576 9673 5.554 153 0.022 6868 6076 7660
Women with prevalent vertebral fracture
65 years 9942 12.533 9192 12.518 750 0.016 48,018 40,402 55,634
70 years 10,821 9.939 10,208 9.920 613 0.019 32,685 22,292 42,312
80 years 10,698 5.451 10,611 5.425 88 0.026 3390 2748 4032
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administration of these supplements based on the amounts of
calcium and vitamin D that are already spontaneously re-
ceived by the patients.
We recently reported that a pharmacological supplementa-
tion of vitamin D and calcium is cost-effective for women and
men aged 60 years with osteoporosis [11]. This finding jus-
tifies the recommendation of the ESCEO working group to
supplement all patients aged over 65 years with increased risk
of fractures with calcium and vitamin D [2, 3]. This European
consensus, however, recommends that dietary sources of nu-
trients are the preferred option for the supplementation of el-
derly subjects and that pharmacological supplementation
should only be targeted to those individuals who do not get
sufficient calcium from their diet [2]. Amazingly, this recom-
mendation was never, before the present trial, justified in
terms of cost-effectiveness. Our study is the first economic
analysis that estimates the cost-effectiveness of calcium and
vitamin D supplementation, given as a vitamin D-fortified
yogurt, and taking into consideration the age (65, 70,
80 years), the osteoporotic status (none, low BMD, PVF),
and the amount of calcium (400 mg, 800 mg, 1200 mg) and
vitamin D (200 IU, 400 IU, 600 IU) needed to reach the RNI.
Whereas a previous study reported the impact of an increased
dairy consumption on reducing the burden of osteoporosis in
terms of health-outcomes and costs [9], our research is the first
to provide a full economic analysis, using a validated and
widely accepted Monte Carlo microsimulation model [13].
Another strength of our study relates to the sensitivity analyses
assessing various supplementation regimens. However, if we
rely on the average values of calcium intake in 25-OH
hydroxyvitamin D serum concentrations reported in the liter-
ature for normal and osteoporotic elderly subjects, and the
RNI for these nutrients [2, 3, 5–8, 22, 23, 29, 31–34], we
can reasonably assume that an intake of two portions of a
fortified yogurt per day in the general population and one
portion in the low BMD and PVF groups, on top of the
existing dietary and pharmacological intakes, would be appro-
priate to ensure an optimal coverage of the calcium and vita-
min D requirements. In this case, this strategy is cost-effective
above 80 years in the general population but as early as
65 years old in patients at increased risk of osteoporotic frac-
ture. For those individuals, from the general population, with a
higher than average spontaneous intake in calcium and vita-
min D, requesting only one portion of yogurt to reach the RNI,
the strategy would be cost-effective from 70 years on while in
those subjects with very low calcium/vitamin D intakes, who
need three portions/day to compensate for their deficiency,
cost-effectiveness will only be observed for all groups, above
80 years. Women with an increased risk of experiencing an
osteoporotic fracture (low BMD or PVF) with an intermediate
but less than average calcium and vitamin D intake, i.e.,
requesting two portions of yogurt per day to reach the RNI,
would face a cost-effective strategy when aged 70 years and
above.
Strength of this study includes the use of a rigorous sys-
tematic review on meta-analyses to assess the effects of calci-
um and vitamin D on fracture risk, which was conducted for
our recent paper assessing the cost-effectiveness of pharma-
cological supplementation in calcium and vitamin D in elderly
men and women with osteoporosis [11]. Our estimates are
also probably conservative for several reasons. First, different
studies showed that calcium and vitamin D supplementation
have other health benefit effects. So, studies suggested that
calcium and vitamin D may reduce the risk for breast cancer
Table 3 Costs, QALYs, and ICER for a supplementation with three portions per day (375 Euros/year)
3 Units/day (€375/year)
Ca/Vit D supplementation No supplementation Incremental ICER (€) 95 % CI
Cost (€) QALYs Cost (€) QALYs Cost (€) QALYs Low (€) High (€)
Women without low BMD or prevalent vertebral fracture
65 years 7592 12.796 6418 12.788 1174 0.009 136,244 16,367 256,121
70 years 8272 10.187 7225 10.177 1047 0.010 104,523 62,106 146,941
80 years 8303 5.618 7728 5.602 575 0.015 37,114 31,264 42,964
Women with low BMD
65 years 11,105 12.656 10,093 12.641 1,012 0.014 71,058 53,694 88,422
70 years 11,505 10.074 10,608 10.057 897 0.018 51,002 45,738 56,266
80 years 10,132 5.570 9712 5.552 420 0.018 23,147 20,598 25,695
Women with prevalent vertebral fracture
65 years 10,290 12.531 9207 12.519 1083 0.012 89,303 79,780 98,826
70 years 11,117 9.934 10,168 9.918 948 0.016 58,001 47,837 68,165
80 years 11,039 5.451 10,633 5.423 407 0.028 14,602 13,502 15,702
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mainly in premenopausal women [35] and colon cancer in
older women [36]. A meta-analysis has also indicated that
vitamin D may have a small beneficial effect on cardiovascu-
lar risk and mortality [37, 38]. Second, we used a conservative
assumption about the efficacy of calcium and vitamin D on
hip fracture. In the article of Boonen et al., high doses of
calcium and vitamin D were associated with a slightly greater
reduction of hip fracture risk [22]. However, real-life studies,
confirming that the administration of yogurt containing high
doses of calcium and vitamin D provide the same extra-
skeletal benefits than pharmacological administration of cal-
cium and vitamin D would be of greatest interest.
Third, at every stage of life, adequate dietary intakes of key
bone nutrients including calcium, vitamin D, and proteins
contribute to muscle and bone health, thereby reducing the
risk of falls, osteoporosis, and fractures in later life [3]. Dairy
products are rich in proteins [33]. There is no clear-cut evi-
dence that patients aged more than 65 years old have a deficit
in protein intake similar to what is reported for calcium and
vitamin D [29]. However, it is possible that our analysis, based
only on the beneficial effects of calcium and vitamin D on
bone, without modeling the potential benefits of proteins un-
derestimates the positive outcomes of dairy products intake.
Our study could have some potential limitations that could
inform further economic evaluations. Like any health eco-
nomics study, there are a large number of assumptions. This
analysis of the cost-effectiveness of yogurt supplementation in
older women is critically dependent on the evidence for effi-
cacy of the intervention. It should be reminded that controver-
sy exists in the literature related to anti-efficacy of calcium
supplements with some recent meta-analyses of the effects
of calcium on hip fracture in community-dwelling older peo-
ple challenging the reduction in fracture risk [39, 40]. We did
not incorporate adherence with dairy products which could
potentially affect the cost-effectiveness of this strategy [41].
Limited information about adherence to dairy products is cur-
rently available including the impact of non-adherence on
treatment efficacy. It should be reminded that in Tang [23]
meta-analysis, compliance of >80 % is necessary to achieve
anti-fracture efficacy. We also made the assumption that by
supplementing patients with variable doses of dairy calcium
and vitamin D, based on their spontaneous intake of these
nutrients (dietary or pharmacological), we would reach the
target of at least 800 IU/day of vitamin D and 1 g/day of
calcium, hence getting a similar clinical benefit on fracture
risk. We acknowledge that this assumption has not been tested
in clinical trials.
In conclusion, our study is the first economic analysis
supporting the cost-effectiveness of dairy products, fortified
with vitamin D, in the armamentarium against osteoporotic
fractures. Dairy products have been repeatedly suggested as
the most appropriate source of calcium and vitamin D supple-
mentation in women at risk of osteoporotic fracture. Based on
the average intake of these nutrients, reported in the literature,
an additional daily intake of two portions in the general pop-
ulation and of one portion in women with low BMD or PVF,
of a dairy product providing 400 mg of calcium and 200 IU of
vitamin D, would be appropriate to meet the RNI for these
nutriments. This strategy would be cost-effective from the age
Fig. 2 a Incremental cost-effectiveness ratio of a supplementation with a
dairy product fortified with vitamin D (400 mg calcium/200 IU vitamin
D) as a function of age and cost of the dairy product (one daily portion:
125 €, two daily portions: 250 €, three daily portions: 375 €) in women
without low bone mineral density or prevalent vertebral fractures. b
Incremental cost-effectiveness ratio of a supplementation with a dairy
product fortified with vitamin D (400 mg calcium/200 IU vitamin D) as
a function of age and cost of the dairy product (one daily portion: 125 €,
two daily portions: 250 €, three daily portions: 375 €) in women with low
bone mineral density. c Incremental cost-effectiveness ratio of a
supplementation with a dairy product fortified with vitamin D (400 mg
calcium/200 IU vitamin D) as a function of age and cost of the dairy
product (one daily portion: 125 €, two daily portions: 250 €, three daily
portions: 375 €) in women with prevalent vertebral fractures
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of 80 years in the general population and as early as 65 years
old in women with low BMD or PVF. We provide different
sensitivity analyses based on the age of the women, the pres-
ence or absence of osteoporosis, and the amount of calcium
and vitamin D needed to meet the RNI.
In future research, adherence of women either in the gen-
eral population or at high risk of osteoporosis to dairy products
might be tested in long-term prospective trials. It would also
be of interest to design willingness to pay studies to better
understand to which extend individuals are ready to add dairy
products to their diet to prevent osteoporosis.
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